Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1629 1654 1674
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18258653 | USE AS SELECTIVE AGONIST OF MELANOCORTIN-4 RECEPTOR | Final Rejection | LG CHEM, LTD. |
| 18266083 | Sulfoximine Pesticides | Final Rejection | BASF SE |
| 17599207 | BRYOSTATIN COMPOUNDS FOR ENHANCEMENT OF IMMUNOTHERAPY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17770704 | USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUND FOR PREVENTION, ALLEVIATION, OR TREATMENT OF DEVELOPMENTAL DISABILITY | Non-Final OA | SK BIOPHARMACEUTICALS CO., LTD. |
| 17618838 | DIBENZYLAMINES AS AMINO ACID TRANSPORT INHIBITORS | Final Rejection | VANDERBILT UNIVERSITY |
| 17745621 | DUAL ANDROGEN RECEPTOR/AKR1C3 INHIBITORS | Final Rejection | Ohio State Innovation Foundation |
| 17924610 | CIRCULATING B CELL SUBPOPULATIONS IN INDOLENT B CELL LYMPHOMA | Non-Final OA | Alexion Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy